Using 18F-FAPI-74 PETCT Imaging to Detect and Monitor Fibrosis in Heart and Lung Diseases

What this Trial Is About

Researchers are investigating a new imaging tracer called 18F-FAPI-74 to detect early fibrosis, or scar tissue, in the heart and lungs. Fibrosis can develop due to various heart and lung diseases and current imaging methods only identify scar tissue after it has formed. This study aims to compare the new tracers imaging ability to standard scans, including PETCT, chest CT, and cardiac MRI, to better detect and monitor fibrosis in people with cardiopulmonary disorders. Participants will receive the 18F-FAPI-74 tracer injected into a vein for PETCT imaging, along with standard imaging tests. They will have two imaging sessions with the tracer, spaced 8 to 12 months apart, to track fibrosis and treatment effects. Additional blood tests and function tests of the heart and lungs will be done at multiple points, including at 3 and 6 months after the first imaging. This allows comparison of the new tracers performance against standard care over time. People in the study will attend six clinic visits over two years, including screening with blood tests and heartlung function tests. Heart patients will also have cardiac MRI scans. The study measures how well the new tracer detects fibrosis compared to standard imaging and monitors changes over time. Blood samples will also be analyzed to explore biological markers of fibrosis. Participants safety and health will be closely monitored throughout the study period.

Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging